Finerenone

Introduction Overview

Generic Name

finerenone

Brand Name

Kerendia

Dosage Form

tablets

Drug Class

Aldosterone receptor antagonists

Pharmacokinetics

Absorption:
Finerenone is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1-2 hours post-dose. It exhibits moderate oral bioavailability and can be taken with or without food without significant impact on absorption. The presence of food does not alter the extent of absorption, allowing flexible dosing schedules for patients. These pharmacokinetic properties facilitate consistent therapeutic plasma levels with once-daily dosing, enhancing patient adherence.

Distribution:
Finerenone has moderate plasma protein binding and distributes preferentially to cardiac and renal tissues due to its molecular structure and affinity for mineralocorticoid receptors (MR). Its volume of distribution supports significant tissue penetration, particularly in target organs affected by chronic kidney disease (CKD) and heart failure (HF). Tissue selectivity is notable compared to steroidal MR antagonists, potentially reducing off-target effects. Distribution is influenced by organ perfusion and patient-specific factors such as renal function.

Metabolism:
Finerenone is extensively metabolized primarily via the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system. Its metabolism involves oxidative pathways leading to inactive metabolites. The dependence on CYP3A4 underscores potential drug-drug interactions with CYP3A4 inhibitors or inducers, which can alter plasma concentrations and impact safety and efficacy. Finerenone is distinguished by its selective, non-steroidal structure, differing metabolically from steroidal MR antagonists, which may influence the safety profile.

Elimination:
The elimination half-life of finerenone is approximately 2 to 3 hours, with metabolites excreted primarily via the renal route and to a lesser extent via biliary/fecal pathways. Renal clearance plays a significant role, and impaired kidney function can alter drug elimination kinetics. Therefore, dosing adjustments based on estimated glomerular filtration rate (eGFR) are recommended. Steady-state concentrations are typically achieved within a few days of daily dosing, supporting its clinical use in chronic conditions.

Dosage Forms

Available Dosage Forms:
Kerendia is supplied as oral film-coated tablets available in three strengths to facilitate titration and personalized dosing: 10 mg, 20 mg, and 40 mg tablets. The tablets contain the active ingredient finerenone along with excipients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, sodium lauryl sulfate, titanium dioxide, and iron oxides used as coloring agents.

Dosages for Adults and Adolescents:
Kerendia is FDA-approved for adult use only and is not indicated for pediatric patients under 18 years of age. For adults with chronic kidney disease associated with type 2 diabetes, initial dosing depends on eGFR: patients with eGFR ≥60 mL/min/1.73 m2 start with 20 mg once daily; those with eGFR between 25 and <60 mL/min/1.73 m2 start at 10 mg once daily. Initiation is not recommended if eGFR is below 25 mL/min/1.73 m2.
For adults with heart failure with left ventricular ejection fraction (LVEF) ≥40%, the target dose is 40 mg once daily if eGFR ≥60, or 20 mg once daily if eGFR is between 25 and <60 mL/min/1.73 m2. Dose adjustments are guided by monitoring serum potassium and renal function.

Specific Patient Populations:
Kerendia treatment initiation is contraindicated in patients with serum potassium levels greater than 5.0 mEq/L due to hyperkalemia risk. Renal function (eGFR) must be carefully evaluated prior to initiation and monitored during therapy. The drug is not recommended during pregnancy or breastfeeding and requires careful consideration in patients with hepatic impairment. Elderly patients may require monitoring given potential changes in pharmacokinetics and comorbidities. Pediatric use has not been established. Dose modification and monitoring are critical in patients receiving concomitant CYP3A4 inhibitors or drugs affecting potassium levels.

Mechanism Of Action

Finerenone, the active ingredient in Kerendia, acts as a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA). Its primary molecular mechanism involves high-affinity binding to mineralocorticoid receptors (MR) located in renal, cardiac, and vascular tissues, thereby preventing aldosterone and MR overactivation. This receptor blockade inhibits the downstream signaling cascades that would otherwise promote inflammation, fibrosis, and oxidative stress.

At the cellular level, MR overactivation induces pro-inflammatory and pro-fibrotic gene expression, leading to tissue remodeling and damage. By antagonizing MR, finerenone reduces the transcription of genes involved in collagen synthesis, inflammatory cytokines, and other mediators responsible for pathological fibrosis and vascular damage. This mitigates progression of chronic kidney disease and cardiovascular events.

Biochemically, finerenone exhibits unique non-steroidal properties, distributing evenly between cardiac and renal tissues and demonstrating less off-target activity compared to steroidal MR antagonists like spironolactone or eplerenone. This contributes to a more favorable safety and tolerability profile. Clinical implications include the reduction of sustained eGFR decline, prevention of end-stage kidney disease, and lowered incidence of cardiovascular death and hospitalizations due to heart failure.

Comparative studies indicate that finerenone's greater selectivity and potency for MR, combined with its distinct tissue distribution, provide enhanced efficacy in reducing cardiorenal morbidity. Clinical trials such as FIDELIO-DKD and FIGARO-DKD have substantiated these benefits, demonstrating significant reductions in renal and cardiovascular adverse outcomes in patients with type 2 diabetes and CKD.

Pharmacological Actions

Selective antagonism of mineralocorticoid receptors to inhibit aldosterone-mediated effects
Reduction of renal inflammation and fibrosis by blocking pro-fibrotic gene expression
Attenuation of cardiac remodeling and prevention of myocardial fibrosis in heart failure
Decreasing oxidative stress and vascular injury in kidney and cardiovascular tissues
Lowering the progression of chronic kidney disease by preserving glomerular function
Cardioprotective effects manifested by reduced risk of cardiovascular death and events
Non-steroidal structure leading to a favorable side effect profile compared to steroidal MR antagonists
Improvement in electrolyte balance by moderating potassium retention and sodium excretion
Reduction of hospitalization rates for heart failure exacerbations
Mitigation of aldosterone-induced endothelial dysfunction and vascular stiffness
Potential to decrease proteinuria and albuminuria in diabetic nephropathy
Modulation of inflammatory signaling pathways in renal and cardiac tissue
Selective tissue targeting with balanced distribution in heart and kidney
Minimal anti-androgenic and hormonal side effects due to specificity
Contribution to slowing eGFR decline and delaying progression to end-stage renal disease

Therapeutic Or Clinical Uses

Treatment of chronic kidney disease (CKD) associated with type 2 diabetes to reduce kidney function decline
Reduction of risk for end-stage kidney disease (ESKD) in patients with diabetic nephropathy
Prevention of cardiovascular death in adults with CKD and type 2 diabetes
Reduction in non-fatal myocardial infarction occurrences related to CKD and diabetes
Management of heart failure with left ventricular ejection fraction (LVEF) ≥ 40% to decrease risk of hospitalization and cardiovascular death
Slowing progression of kidney fibrosis and inflammation in chronic cardiometabolic diseases
Adjunctive therapy in diabetic kidney disease to preserve renal function
Lowering incidence of hospitalization for heart failure exacerbation
Reducing morbidity related to cardiorenal syndrome in patients with comorbid diabetes and CKD
Use in patients at high risk for cardiovascular events due to mineralocorticoid receptor overactivation
Potential to improve quality of life by stabilizing heart and kidney functions in at-risk populations
Adjunct to standard of care for CKD in diabetes including ACE inhibitors or ARBs
Treatment aimed at preventing dialysis or kidney transplantation necessity in CKD progression
Therapeutic option for patients intolerant to steroidal mineralocorticoid receptor antagonists
Reduction in electrolyte disturbances commonly associated with mineralocorticoid receptor hyperactivity

Side Or Adverse Effects

Hyperkalemia (high blood potassium), which may manifest as nausea, weakness, tingling, chest pain, or irregular heartbeats
Hyponatremia (low blood sodium), presenting with headache, confusion, memory problems, weakness, or balance difficulties
Hypotension (low blood pressure), reported in a significant subset of patients, which may cause dizziness or fainting
Allergic reactions including hives, swelling of the face, lips, tongue, or throat, and difficulty breathing
Gastrointestinal disturbances such as nausea or abdominal discomfort
Fatigue or generalized weakness potentially related to electrolyte imbalances
Elevated serum creatinine or transient worsening of renal function during initiation or dosage adjustments
Possible dizziness or lightheadedness particularly when standing up quickly
Increased risk of hyperkalemia when given concomitantly with potassium supplements or potassium-sparing agents
Potential interactions leading to elevated drug levels when co-administered with CYP3A4 inhibitors
Headache and musculoskeletal pain reported in some cases
Potential for worsening liver function in patients with severe hepatic impairment
Injection site reactions are not applicable as Kerendia is oral; however, tablet discomfort due to crushing is rare
Risk of dehydration or electrolyte disturbances particularly in elderly or volume-depleted patients
Rare but serious cardiac arrhythmias due to significant hyperkalemia

Precautions

Monitor serum potassium and renal function before starting and periodically during treatment to mitigate hyperkalemia risk
Avoid initiating therapy if serum potassium exceeds 5.0 mEq/L or eGFR is below 25 mL/min/1.73 m2
Use caution in patients with severe hepatic impairment or adrenal insufficiency
Avoid concomitant use with potassium supplements or potassium-containing salt substitutes unless supervised by a healthcare provider
Adjust dosing based on renal function and potassium levels, with frequent monitoring especially after dose changes
Advise patients to avoid grapefruit and grapefruit juice due to potential interaction and increased drug levels
Consider risk-benefit profile carefully in elderly patients who may have multiple comorbidities affecting drug metabolism
Pregnancy risk is unknown; finerenone is not recommended in pregnant or breastfeeding women
Educate patients on symptoms of hyperkalemia and instruct immediate reporting if they occur
Avoid use with strong CYP3A4 inhibitors or monitor potassium and adjust dose if moderate inhibitors are used concomitantly
Assess adrenal gland function prior to initiation as adrenal gland insufficiency is a contraindication
Ensure accurate patient history regarding liver disease and electrolyte disturbances
Perform baseline and routine cardiovascular assessments particularly in heart failure patients
Avoid sudden discontinuation to prevent rebound worsening of cardiovascular or kidney disease
Caution when used in combination with other medications that alter potassium or renal function

Warnings

Risk of serious hyperkalemia potentially leading to fatal arrhythmias—requires close monitoring of potassium
Contraindicated in patients with known hypersensitivity to finerenone or excipients
Use with strong CYP3A4 inhibitors can lead to increased finerenone plasma concentrations and toxicity
Not recommended for patients with severe renal impairment or eGFR less than 25 mL/min/1.73 m2
Potential for low blood pressure causing dizziness or fainting, especially in volume-depleted patients
Safety and efficacy have not been established in pediatric populations under 18 years
Possible risk of fetal harm; discontinue if pregnancy occurs or in women planning pregnancy
Breastfeeding is contraindicated during treatment and for at least 1 day after last dose
Avoid use in patients with adrenal insufficiency due to potential worsening of adrenal function
Serious hypersensitivity reactions including angioedema have been reported rarely
May cause electrolyte imbalances necessitating vigilant laboratory monitoring
Do not use concurrently with potassium-sparing diuretics without close monitoring
Abrupt dose changes should be avoided due to risk of destabilizing electrolytes and renal function
Patients should be warned about potential signs of electrolyte disturbances and cardiac symptoms
Closely monitor patients with underlying cardiovascular disease given the risk of adverse cardiac events secondary to electrolyte abnormalities

Contraindication

Known hypersensitivity or allergy to finerenone or any component of the formulation
Patients with adrenal insufficiency or other significant adrenal gland disorders
Hyperkalemia with serum potassium levels greater than 5.0 mEq/L prior to treatment initiation
Severe renal impairment defined as eGFR below 25 mL/min/1.73 m2
Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, ritonavir)
Pregnant women due to potential fetal risk and lack of safety data
Breastfeeding women during treatment and for at least one day post-treatment
Patients taking potassium-sparing diuretics or potassium supplements unless under strict medical supervision
History of serious allergic reactions to mineralocorticoid receptor antagonists
Patients with conditions predisposing to hyperkalemia not manageable with monitoring
Concomitant use with drugs contraindicated due to pharmacokinetic interactions causing elevated finerenone levels
Uncontrolled hypotension or significant volume depletion at baseline
Use in pediatric patients below 18 years old due to lack of safety and efficacy data

Drug Interactions

Strong CYP3A4 inhibitors such as clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, ritonavir, lopinavir, and cobicistat may increase finerenone plasma levels, raising toxicity risk and requiring avoidance or monitoring
Moderate and weak CYP3A4 inhibitors like amiodarone, erythromycin, fluconazole, diltiazem, verapamil, and conivaptan require careful potassium monitoring and possible finerenone dose adjustments
Potassium supplements or potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene) can elevate serum potassium levels and increase hyperkalemia risk when combined
Nonsteroidal anti-inflammatory drugs (NSAIDs) may impair renal function further when used concomitantly, necessitating caution
Certain antiviral agents used for HIV or hepatitis C, including boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, and telaprevir, can alter finerenone metabolism or increase adverse event risk
Concurrent use with diuretics can influence electrolyte balance and blood pressure, requiring clinical monitoring
Drugs that affect renal function or eGFR may necessitate finerenone dosage modifications
Grapefruit and grapefruit juice can inhibit CYP3A4 enzymes and increase finerenone exposure, so their consumption should be avoided
Concomitant use with endocrine therapies or steroidal MR antagonists is not recommended without close supervision
Interactions with antihypertensive medications may potentiate hypotensive effects and require dose adjustments
Avoid combining with nephrotoxic agents which may exacerbate renal impairment
Co-administration with P-glycoprotein substrates/inhibitors has not shown clinically relevant interactions but should be monitored
Some antibiotics such as telithromycin may interfere with finerenone metabolism leading to increased systemic exposure
Drug interactions may impact therapeutic efficacy; comprehensive medication review is critical when starting or stopping Kerendia
Patients should be advised to inform healthcare providers of all medications, including over-the-counter and herbal supplements

Preparations Of The Drug

Oral film-coated tablets available in strengths of 10 mg, 20 mg, and 40 mg of finerenone
Tablets contain inactive ingredients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, and sodium lauryl sulfate
The tablet film coating includes hypromellose, titanium dioxide, talc, and iron oxides which serve as coloring agents (red for 10 mg and yellow for 20 mg)
Available as prescription-only medication for oral administration once daily
Stored at controlled room temperature between 68°F to 77°F (20°C to 25°C), protected from excessive moisture and light
Supply typically dispensed in bottles or blister packs depending on the manufacturer and prescription requirements
Oral tablets can be crushed and mixed with water or soft foods such as applesauce if swallowing difficulties are present, facilitating administration in special populations
Provided with a medication guide detailing dosage, administration, side effects, and precautions for patient awareness
Manufactured in compliance with Good Manufacturing Practices ensuring purity and potency
Specific lot numbers and expiration dates are provided to maintain traceability and drug integrity
No intravenous or alternative formulations currently approved; oral tablet is the sole marketed formulation
Available through specialty pharmacies with coverage depending on insurance and regional availability
Dispensed with dosing titration guidelines to facilitate safe initiation and monitoring
Packaging includes child-resistant caps and appropriate labeling in accordance with regulatory standards
Prescribed exclusively for adult patients meeting FDA-approved indications